Cannabinoid-Phenylethanoid Formulation for Synergistic Inflammation Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for cannabinoid formulations with increased efficacy and suitability for traditional drug delivery methods that provide synergistic anti-inflammatory effects, particularly for treating inflammatory conditions.

Innovation Solution

A combination formulation comprising cannabinoids, such as CBD, and phenylethanoids, such as oleocanthal, in specific molar ratios, suitable for various administration routes, including oral, topical, and pulmonary, to reduce inflammation by decreasing the secretion of inflammatory cytokines by chondrocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cannabinoid formulations are developed for anti-inflammatory treatment, then therapeutic efficacy is improved, but suitability for traditional drug delivery methods and synergistic effects are insufficient

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidsuitability for traditional drug delivery methods

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines cannabinoids (CBD) with phenylethanoids (oleocanthal) in a unified formulation to create synergistic anti-inflammatory effects. This merging of two different compound classes enhances therapeutic efficacy while maintaining compatibility with traditional drug delivery methods such as oral capsules, topical creams, and inhalable formulations.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation containing both cannabinoid and phenylethanoid compounds. This composite approach allows the formulation to leverage the beneficial properties of both compound classes while achieving improved anti-inflammatory efficacy and broader adaptability to various delivery systems.

Inventive Principle:

Principle #40Composite materials

2Device complexity

If single cannabinoid formulations are used, then formulation simplicity is maintained, but anti-inflammatory efficacy is insufficient compared to combination formulations

Engineering Contradiction:

Improveformulation simplicityVSAvoidanti-inflammatory efficacy

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent merges cannabinoids and phenylethanoids into a combination formulation that delivers synergistic anti-inflammatory effects. The combination approach enhances efficacy beyond what single cannabinoid formulations can achieve, while the formulation is designed to maintain practical simplicity for manufacturing and administration.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12576094B2Combination cannabinoid-phenylethanoid formulation for treatment of inflammation and methods related thereto

Publication Date: 2026.03.17 CANOLE LLC

AI summary

The present invention describes cannabinoid formulations that combine cannabinoids, such as CBD, with other active agents within the phenylethanoid class of compounds, such as oleocanthal, which, in combination, provide synergistic anti-inflammatory effects. These combination preparations are capable of increasing anti-inflammatory effects when compared to each individual compound alone, and are further capable of delivery through a variety of administration routes.